Santarus Inc.

Company Website

10590 W. Ocean Air Drive., Suite 200
San Diego, CA 92130

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Santarus Inc.

Market Cap as of 7/03/2014

Market Cap as of 07/02/2013

$1,392,778,320

Market Cap as of 06/26/2012

$440,151,093

Market Cap as of 01/04/2012

$197,833,700

Market Cap as of 06/20/2011

$195,910,800

Market Cap as of 01/06/2011

$207,648,900

Exchange and Ticker Symbol

Nasdaq: SNTS

Fields of Research

Engages in acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists

Major Products

Mmetformin hydrochloride extended release tablets (Glumetza), bromocriptine mesylate tablets (CYCLOSET), omeprazole/sodium bicarbonate capsules and powder for oral suspension (Zegerid), Budesonide MMX, Rhucin, Rifamycin SV MMX, SAN-300

View all the companies in San Diego Publicly Traded Companies

Santarus Inc.

Market Cap as of 7/03/2014

Exchange

NASDAQ GS

Ticker

SNTS

Executives

Gerald Proehl (profile)

  • Chief Executive Officer
  • President

Related News

Articles

Santarus stock opens strong

Shares in San Diego biotech company Santarus Inc. (Nasdaq: SNTS) jumped more than 6 percent this morning after it was named the "Bull of the Day" by Zacks Equity Research and also got a strong nod from the Motley Fool stock pick site, with a pun-laden reference to the company's concentration on the intestines.

E&Y names six winners of the Entrepreneur of the Year award

Ice chips flew when chainsaw-wielding women in heels opened Ernst & Young’s Entrepreneur of the Year 2013 awards Thursday in San Diego with the sculpting of the E&Y logo out of ice blocks.

Santarus says FDA accepts Ruconest application

Santarus Inc. (Nasdaq: SNTS) and Pharming Group said Tuesday that the Food and Drug Administration accepted their marketing application for the hereditary angioedema drug Ruconest, and will make a decision in 10 months.

Santarus jumps on 2Q earnings and stronger outlook

Shares of San Diego-based Santarus Inc. (Nasdaq: SNTS) climbed Wednesday after the drugmaker posted strong second-quarter results and raised its financial forecasts for the year.

Endochoice sues Santarus for infringement over logos

(Bloomberg) -- Endochoice Inc., a manufacturer of products used to diagnose and treat gastrointestinal diseases, filed a trademark infringement lawsuit against San Diego-based competitor Santarus Inc.

Salix Pharma will buy Santarus for $2.12 billion

Salix Pharmaceuticals (Nasdaq: SLXP) will buy San Diego-based Santarus (Nasdaq: SNTS) for about $2.12 billion to add to its roster of drugs.

Similar Companies

In-Vitro Diagnostic Substance Manufacturing325413
IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES2835
Drugs and Druggists' Sundries Merchant Wholesalers424210
DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS' SUNDRIES5122
Pharmacies and Drug Stores446110
DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS' SUNDRIES5122
Cosmetics, Beauty Supplies, and Perfume Stores446120
DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS' SUNDRIES5122
Subscribe Today!